TARDIVE DYSKINESIA
Clinical trials for TARDIVE DYSKINESIA explained in plain language.
Never miss a new study
Get alerted when new TARDIVE DYSKINESIA trials appear
Sign up with your email to follow new studies for TARDIVE DYSKINESIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a drug calm uncontrollable movements? new trial tests tetrabenazine
Disease control CompletedThis Phase 3 trial tested whether tetrabenazine (Xenazine) can reduce involuntary movements in people with tardive dyskinesia, a condition caused by long-term use of antipsychotic medications. Fifty-four adults with persistent symptoms were randomly assigned to receive either tet…
Matched conditions: TARDIVE DYSKINESIA
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug shows promise in taming tardive dyskinesia movements
Symptom relief CompletedThis study tested a drug called SD-809 (deutetrabenazine) in 298 people with moderate to severe tardive dyskinesia, a condition causing uncontrollable movements. Participants received either the drug or a placebo for 12 weeks. The main goal was to see if the drug reduced the seve…
Matched conditions: TARDIVE DYSKINESIA
Phase: PHASE3 • Sponsor: Auspex Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Valbenazine shows promise for easing involuntary movements in tardive dyskinesia
Symptom relief CompletedThis completed Phase 4 study tested valbenazine in 59 adults with tardive dyskinesia (involuntary muscle movements) caused by psychiatric medications. Participants had schizophrenia, bipolar disorder, or major depression. Over 24 weeks, researchers measured changes in quality of …
Matched conditions: TARDIVE DYSKINESIA
Phase: PHASE4 • Sponsor: Neurocrine Biosciences • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
New drug shows promise for taming involuntary movements
Symptom relief CompletedThis study tested a once-daily drug called MT-5199 in 256 adults with tardive dyskinesia, a condition causing uncontrollable movements. The goal was to see if the drug could reduce these movements safely. Participants had mental health conditions like schizophrenia or bipolar dis…
Matched conditions: TARDIVE DYSKINESIA
Phase: PHASE2, PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC